BRIDGEBIO PHARMA INC.

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

20 May 2025 06:30:00 By Nasdaq GlobeNewswire

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

19 May 2025 11:33:39 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 May 2025 15:01:00 By Nasdaq GlobeNewswire

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

13 May 2025 06:30:00 By Nasdaq GlobeNewswire

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

12 May 2025 06:30:00 By Nasdaq GlobeNewswire

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

07 May 2025 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

29 Apr 2025 15:01:00 By Nasdaq GlobeNewswire

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

22 Apr 2025 06:30:36 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2025 15:01:00 By Nasdaq GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

31 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

27 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

24 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 Mar 2025 15:00:00 By Nasdaq GlobeNewswire

BridgeBio Announces CFO Succession

17 Mar 2025 15:01:00 By Nasdaq GlobeNewswire

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

26 Feb 2025 01:49:38 By Nasdaq GlobeNewswire

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

24 Feb 2025 15:09:42 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

20 Feb 2025 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

13 Feb 2025 15:01:00 By Nasdaq GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

11 Feb 2025 08:21:48 By Nasdaq GlobeNewswire